Wednesday, Feb 23, 2005
Wednesday, Feb 23, 2005 |
| Business | ||||
|
News:
Front Page |
National |
Tamil Nadu |
Andhra Pradesh |
Karnataka |
Kerala |
New Delhi |
Other States |
International |
Opinion |
Business |
Sport |
Miscellaneous |
Engagements |
Advts: Classifieds | Employment | Business
By Ramnath Subbu
NASHIK, FEB. 22. GlaxoSmithKline (GSK) today announced its plans to foray into the vaccines business in India. Patrick Florent, Vice President, Global Industrial Operations, GlaxoSmithKline Bio- logicals, today laid the foundation for a new facility coming up at the GSK facility here. The facility is expected to commence operations in early 2006 and entails an investment of around Rs. 75-80 crores. Speaking to the media here, Mr. Florent said, "So far, GSK's vaccine manufacturing activity has only been in Europe. We have decided to transfer some of the manufacturing activity outside Europe and one of these facilities would be in India.'' The plant will mainly do filling and packaging of the vaccines. The Nashik facility will be managed by Belgium through GSK Asia (formerly SB Asia). This is being done to keep the technological data in a closely guarded manner and the proprietary rights will be vested with this 100 per cent subsidiary (GSK Asia). While the investments made by GSK Asia will not appear on the figures of GSK Pharmaceuticals India (the listed company), the turnover will be reflected in the listed company as marketing of all the products will be through GSK Pharmaceuticals. "All transactions are at an arm's length arrangement,'' said Mr. S. Kalyanasundaram, Vice President, South Asia and Managing Director, GSK India. While declining to comment on the capacities being set up, Mr. Kalyanasundaram, said, "We can cater to the entire market from this facility. We are focusing on products that are differentiated and with growth prospects. Vaccines will be a focus area for at least ten years to come.''GSK's Rotavirus vaccine is awaiting regulatory approval and should be introduced here in 18-24 months. Mr. Sundaram also said the company would bring the vaccine for cervical cancer — Cervarix — to India by 2007.
Printer friendly
page
News:
Front Page |
National |
Tamil Nadu |
Andhra Pradesh |
Karnataka |
Kerala |
New Delhi |
Other States |
International |
Opinion |
Business |
Sport |
Miscellaneous |
Engagements |
|
|
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2005, The
Hindu. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu
|
